Coiled Therapeutics

Cancer tumour
#Coiled Therapeutics #Oncology #Phase I trial #Solid tumours

First-in-class TACC3 inhibitor for solid tumours shows 80% CBR

Coiled Therapeutics has provided an update on its Phase I/II clinical trial evaluating AO-252, a first-in-class TACC3 inhibitor, in patients with advanced solid tumours.  According to the data, the transition to a Twice-Daily (BID) dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate (CBR), a… Read More

#Cancer Research #News

#Coiled Therapeutics #Drug discovery #Oncology #Precision medicine

Coiled Therapeutics completes transition to clinical-stage company

Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange.  Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary… Read More

#Business & Investment #News #Start-up Zone